Economic Impacts of Drug Resistant Infections on Cancer Care
Authors: Mo Putera, David McKinney, Chloe Lee1, Shalini Jayasekar Zürn2, Sonali Johnson2 and Scott Howard3, 4 1Alliance for Reducing Microbial Resistance, 2Union of International Cancer Control, 3Resonance 4Yeolyan Hematology-Oncology Center Key messages: Antimicrobial resistance (AMR) undermines the $200 billion spent globally on cancer medicines each year. Drug-resistant infections (DRI) cause excess mortality, increase hospitalisation costs, and erode the health gains that modern...
.png)